Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.68 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.68 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.68 |
| ▸ | JAK3 | P52333 | 3/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | JAK1 | P23458 | 1/20 | 0.64 |
| ▸ | TTK | P33981 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | TXK | P42681 | 1/20 | 0.64 |
| ▸ | BLK | P51451 | 1/20 | 0.64 |
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | ITK | Q08881 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18778502 | 0.92 | EGFR (0.81) | EGFRJAK3BTKITK | |
| SCHEMBL17197333 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4JAK3 | |
| SCHEMBL10127950 | 0.88 | EGFR (0.78) | EGFRERBB4JAK3JAK2FLT3 | |
| SCHEMBL10128034 | 0.88 | EGFR (0.66) | EGFRERBB2ERBB3ERBB4JAK3 | |
| SCHEMBL10128042 | 0.88 | EGFR (0.86) | EGFRERBB4JAK3JAK2JAK1 | |
| SCHEMBL12518488 | 0.85 | EGFR (0.77) | EGFRERBB4JAK3JAK2JAK1 | |
| SCHEMBL18778474 | 0.84 | EGFR (0.82) | EGFRERBB2ERBB3ERBB4JAK3 | |
| SCHEMBL5584209 | 0.84 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4BTK | |
| SCHEMBL10128014 | 0.84 | EGFR (0.64) | EGFRERBB4JAK3JAK2FLT3 | |
| SCHEMBL18778464 | 0.83 | EGFR (0.69) | EGFRJAK3BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885ERBB3 4/4885 |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885ERBB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.